Table S1.
Baseline patient characteristics: demographics and co-morbidities
| Variable | EHa (n=979)b | OH (n=979)b | P-valuec |
|---|---|---|---|
| Age at IPD (years) | |||
| Mean (SD) | 40.5 (25.9) | 40.5 (25.9) | 0.708 |
| Median (IQR) | 41 (13, 64) | 41 (13, 64) | |
| Categorized | N/Ad | ||
| Pediatric (6–11 years), n (%) | 190 (19.4%) | 190 (19.4%) | |
| Adult (12–60 years), n (%) | 498 (50.9%) | 498 (50.9%) | |
| Elderly (61–80 years), n (%) | 291 (29.7%) | 291 (29.7%) | |
| Sex | N/Ad | ||
| Male, n (%) | 439 (44.8%) | 439 (44.8%) | |
| Female, n (%) | 540 (55.2%) | 540 (55.2%) | |
| Smoking status | 0.563 | ||
| Nonsmoker, n (%) | 610 (62.3%) | 604 (61.7%) | |
| Current smoker, n (%) | 127 (13.0%) | 138 (14.1%) | |
| Ex-smoker, n (%) | 196 (20.0%) | 195 (19.9%) | |
| Unknown, n (%) | 46 (4.7%) | 42 (4.3%) | |
| % Predicted PEFe | |||
| Mean (SD) | 84.3 (22.6) | 84.3 (24.9) | 0.937 |
| Median (IQR) | 85.5 (68.7, 99.1) | 83.9 (66.6, 100.8) | |
| Patients, n | 545 | 590 | |
| Year of IPD | |||
| Mean (SD) | 2007.9 (1.7) | 2007.9 (1.5) | N/Ad |
| Median (IQR) | 2008 (2007, 2009) | 2008 (2007, 2009) | |
| CCI score | <0.001 | ||
| 0 | 475 (48.5%) | 578 (59.0%) | |
| 1–4 | 401 (41.0%) | 313 (32.0%) | |
| 5+ | 103 (10.5%) | 88 (9.0%) | |
| Co-morbidities | |||
| Rhinitis,f n (%) | 237 (24.2%) | 296 (30.2%) | 0.003 |
Notes:
a
These patients were on OH during their baseline year but were switched to EH at IPD;
b
except where noted;
c
conditional logistic regression;
d
matching variable;
e
see Figure S1 for age-specific PEF equations used;
f
rhinitis diagnosis and/or prescription for rhinitis drugs. Easyhaler® (Orion Pharma UK Ltd, Newbury, Berkshire, England).
Abbreviations: CCI, Charlson co-morbidity index; EH, Easyhaler®; IPD, index prescription date; IQR, interquartile range; N/A, not applicable; OH, other inhalers; PEF, peak expiratory flow; SD, standard deviation.